Immutep Net Income From Continuing Ops Over Time
| IMMP Stock | USD 2.87 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immutep Performance and Immutep Correlation. Can Biotechnology industry sustain growth momentum? Does Immutep have expansion opportunities? Factors like these will boost the valuation of Immutep. Market participants price Immutep higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Immutep demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.41) | Revenue Per Share | Quarterly Revenue Growth 0.095 | Return On Assets | Return On Equity |
Immutep Ltd ADR's market price often diverges from its book value, the accounting figure shown on Immutep's balance sheet. Smart investors calculate Immutep's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Immutep's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Immutep's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immutep is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immutep's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Immutep Ltd ADR and related stocks such as ProQR Therapeutics, Candel Therapeutics, and Allogene Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRQR | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (12.1 M) | (29 M) | (39.1 M) | (43.7 M) | (37.1 M) | (56.7 M) | (46.6 M) | (61.7 M) | (64.9 M) | (27.7 M) | (27.8 M) | (25 M) | (26.2 M) |
| CADL | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (17.7 M) | (36.1 M) | (18.8 M) | (31.9 M) | (55.2 M) | (49.7 M) | (47.2 M) |
| ALLO | (24 K) | (24 K) | (24 K) | (24 K) | (24 K) | (24 K) | (24 K) | (24 K) | (211.5 M) | (184.6 M) | (250.2 M) | (257 M) | (332.6 M) | (332.9 M) | (257.6 M) | (231.8 M) | (243.4 M) |
| CAPR | (4.9 M) | (4.9 M) | (1.9 M) | (8.9 M) | (6.2 M) | (12.9 M) | (18.8 M) | 2.4 M | (15.2 M) | (7.6 M) | (13.7 M) | (20 M) | (29 M) | (29.2 M) | (40.5 M) | (36.4 M) | (34.6 M) |
| EDIT | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (72.9 M) | (97.2 M) | (120.3 M) | (110 M) | (133.7 M) | (116 M) | (192.5 M) | (220.4 M) | (195.1 M) | (237.1 M) | (213.4 M) | (224.1 M) |
| MREO | (480 M) | (480 M) | (480 M) | (480 M) | (480 M) | (480 M) | (28.4 M) | (38.8 M) | (32 M) | (34.8 M) | (163.6 M) | 12.7 M | (34.2 M) | (29.5 M) | (43.3 M) | (49.7 M) | (52.2 M) |
| VNDA | (9.8 M) | (9.8 M) | (27.7 M) | (20.3 M) | 20.1 M | (40.2 M) | (18 M) | (15.6 M) | 25.2 M | 115.6 M | 23.3 M | 33.2 M | 6.3 M | 11.8 M | (18.9 M) | (21.7 M) | (20.6 M) |
| CABA | (333.3 K) | (333.3 K) | (333.3 K) | (333.3 K) | (333.3 K) | (333.3 K) | (333.3 K) | (333.3 K) | (12.2 M) | (16.9 M) | (33.3 M) | (46.3 M) | (53 M) | (67.7 M) | (115.9 M) | (104.3 M) | (99.1 M) |
| ACHV | (14.7 M) | (14.7 M) | (21.1 M) | (31.8 M) | (26.2 M) | (16.8 M) | (20.1 M) | (10.6 M) | (12.7 M) | (16.4 M) | (14.7 M) | (33.2 M) | (42.4 M) | (35.6 M) | (39.8 M) | (35.8 M) | (37.6 M) |
| TRDA | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (26.5 M) | (51.2 M) | (94.6 M) | (21.8 M) | 65.6 M | 75.5 M | 79.2 M |
Immutep Ltd ADR and related stocks such as ProQR Therapeutics, Candel Therapeutics, and Allogene Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Immutep Ltd ADR | IMMP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Australia Square, Sydney, |
| Exchange | NASDAQ Exchange |
USD 2.87
Additional Tools for Immutep Stock Analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.